医学
三苯氧胺
乳腺癌
内分泌系统
肿瘤科
佐剂
内科学
芳香化酶抑制剂
辅助治疗
癌症
疾病
生活质量(医疗保健)
临床试验
芳香化酶
激素
妇科
护理部
作者
Nicolò Matteo Luca Battisti,Ian Smith
标识
DOI:10.1016/j.ejca.2022.05.028
摘要
Late recurrences are a key challenge for patients with early-stage oestrogen receptor-positive breast cancer, with the risk of disease relapse continuing steadily from 5 to more than 20 years after diagnosis. Five years of adjuvant endocrine therapy with tamoxifen or an aromatase inhibitor was shown many years ago to improve survival. More recently, the trials of extended adjuvant endocrine therapy for more than 5 years have shown a further small gain, but with an associated small risk of increased long-term toxicity including bone loss, cardiovascular impairment and impaired quality of life. This review describes the efficacy and safety of extended endocrine therapy, the optimal selection criteria for patient benefit and the potential for novel agents to improve long-term outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI